| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
3,5-Dimethoxybenzoic acid targets fungal pathogens such as A. rabiei, exhibiting antifungal activity. It is also used as a reagent in the synthesis of resveratrol analogues and quinone reductase 2 inhibitors. As an intermediate for anticancer agents, it may target pathways involved in cancer cell proliferation, including VEGFR-2, ERK-2, and Abl-1. The compound's antioxidant and anti-inflammatory activities suggest it may target oxidative stress and inflammatory pathways.
|
|---|---|
| ln Vitro |
In vitro, 3,5-Dimethoxybenzoic acid demonstrates antifungal activity against A. rabiei. It also exhibits anti-inflammatory, antioxidant, and skin regeneration effects in cell-based assays. The compound is used as a building block for synthesizing bioactive molecules, including anticancer agents that inhibit VEGFR-2, ERK-2, and Abl-1. These in vitro activities support its use in drug discovery and development for antifungal, anticancer, and dermatological applications.
|
| ln Vivo |
In vivo, 3,5-Dimethoxybenzoic acid has demonstrated skin regeneration and anti-wrinkle effects, suggesting potential dermatological applications. Its antifungal activity observed in vitro requires further validation in animal models of fungal infection. The compound's role as an intermediate for anticancer agents suggests potential in vivo applications in cancer therapy, although direct in vivo efficacy data are limited. Further studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 3,5-Dimethoxybenzoic acid include antifungal susceptibility testing against A. rabiei using broth microdilution methods to determine MIC values. Antioxidant activity is assessed using DPPH or ABTS radical scavenging assays. Anti-inflammatory activity is evaluated by measuring inhibition of COX-1/COX-2 or cytokine production. For anticancer applications, the compound's inhibitory activity against VEGFR-2, ERK-2, and Abl-1 is assessed using kinase activity assays with appropriate substrates. All assays are performed in triplicate with appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for 3,5-Dimethoxybenzoic acid are conducted using various cell lines depending on the application. For antifungal studies, fungal cultures are used to assess growth inhibition. For anticancer research, cancer cell lines (e.g., those expressing VEGFR-2 or Abl-1) are treated with compound concentrations ranging from 0.1-100 μM for 24-72 hours. Cell viability is assessed using MTT assays. Anti-inflammatory activity is evaluated in macrophage cell lines by measuring cytokine production. Skin regeneration effects are assessed in keratinocyte or fibroblast cultures. Experiments include vehicle controls and appropriate positive controls.
|
| Animal Protocol |
In vivo animal studies with 3,5-Dimethoxybenzoic acid are limited, as the compound is primarily used as a research intermediate and building block. Dermatological studies may be conducted in animal models of skin aging or wound healing. The compound is applied topically or administered systemically at appropriate doses. Skin regeneration and anti-wrinkle effects are assessed by histological analysis and measurement of skin parameters. Antifungal efficacy is evaluated in models of fungal infection. Each group consists of 6-10 animals with appropriate vehicle controls.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3,5-Dimethoxybenzoic acid have not been extensively characterized. As a small, polar aromatic acid (MW 182.17), it is expected to have moderate oral bioavailability with rapid absorption from the gastrointestinal tract. The compound likely undergoes hepatic metabolism, including O-demethylation and conjugation, with elimination via renal excretion. The methoxy groups may affect its metabolic stability and pharmacokinetic profile. Detailed PK parameters require further investigation in preclinical species.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3,5-Dimethoxybenzoic acid indicate that it is generally considered safe at research doses. No significant acute toxicity has been reported. The compound is an aromatic organic acid found in natural sources and used as a pharmaceutical intermediate. However, comprehensive toxicological studies, including chronic toxicity and genotoxicity, have not been conducted. As with all research chemicals, appropriate safety precautions should be taken during handling, and the compound should be used only for research purposes.
|
| References | |
| Additional Infomation |
3,5-Dimethoxybenzoic acid is a methoxybenzoic acid, meaning benzoic acid is substituted with methoxy groups at the 3 and 5 positions. It is a plant metabolite and the conjugate acid of 3,5-dimethoxybenzoic acid esters. It has been reported to be found in Rhodiola polyanthum and Melia azedarach, and relevant data are available for reference.
3,5-Dimethoxybenzoic acid is a versatile building block in organic synthesis with applications in pharmaceutical and agrochemical development. It exhibits antifungal activity and can be used as an intermediate for anticancer agents. The compound also has anti-wrinkle, anti-inflammatory, antioxidant, and skin regeneration effects. It is used in the synthesis of resveratrol analogues and quinone reductase 2 inhibitors. Not approved for clinical therapeutic use; intended for research purposes only. |
| Molecular Formula |
C₉H₁₀O₄
|
|---|---|
| Molecular Weight |
182.17
|
| Exact Mass |
182.057
|
| CAS # |
1132-21-4
|
| PubChem CID |
14332
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
340.7±22.0 °C at 760 mmHg
|
| Melting Point |
178-180 °C(lit.)
|
| Flash Point |
138.9±15.8 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.533
|
| LogP |
2.03
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
169
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IWPZKOJSYQZABD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10O4/c1-12-7-3-6(9(10)11)4-8(5-7)13-2/h3-5H,1-2H3,(H,10,11)
|
| Chemical Name |
3,5-dimethoxybenzoic acid
|
| Synonyms |
3,5Dimethoxybenzoic acid; 3,5 Dimethoxybenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~548.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
